Sunnyvale, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that its physician-prescribed finger stick allergy testing services are now available in-network from a leading commercial health insurance company. In-network healthcare providers enjoy advantages in the healthcare markets including greater doctor and patient access, simplified billing and streamlined reimbursement. The contracted top five commercial health insurer provides premium healthcare services to tens of millions of Americans and reports aggregate annual revenues exceeding $40,000,000,000 ($40 billion).
Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, fulfilled an FDA clinical instrumentation contract, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by the Centers for Medicare and Medicaid Services, launched the Patient Data Solutions allergy portal for doctors and clinics, celebrated 25 years of company operations, announced an allergy testing services agreement with a major health and wellness provider, provided a letter to shareholders from the company’s Chief Executive Officer, aced four consecutive rounds of proficiency testing, received endorsement by First Pediatrics Medical Group and doubled the number of clinics in its nationwide network to more than 400. In-network allergy testing services privileges with a major healthcare insurer are likely to drive fiscal year 2019 (FY2019) revenues and earnings.
CEO Rene Schena states, “We are delighted to report in-network status for our premium allergy testing services with a major commercial health insurer as a means of more easily serving, via their doctors, the nearly 60 million Americans with allergy and asthma symptoms. In-network access to our simple and convenient personalized healthcare solution for allergy detection and treatment fits squarely within our mission of improving health and wellness through greater awareness and preventative medicine.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve human health and wellness. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com